- Home
- RDHL vs MBIO Comparison
RDHL vs MBIO Comparison
Compare RDHL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- MBIO
- Stock Information
- Founded
- RDHL 2009
- MBIO 2015
- Country
- RDHL Israel
- MBIO United States
- Employees
- RDHL N/A
- MBIO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- MBIO Health Care
- Exchange
- RDHL Nasdaq
- MBIO Nasdaq
- Market Cap
- RDHL 6.8M
- MBIO 7.3M
- IPO Year
- RDHL N/A
- MBIO N/A
- Fundamental
- Price
- RDHL $2.45
- MBIO $1.44
- Analyst Decision
- RDHL
- MBIO Strong Buy
- Analyst Count
- RDHL 0
- MBIO 1
- Target Price
- RDHL N/A
- MBIO $100.00
- AVG Volume (30 Days)
- RDHL 121.9K
- MBIO 66.3K
- Earning Date
- RDHL 04-11-2025
- MBIO 05-14-2025
- Dividend Yield
- RDHL N/A
- MBIO N/A
- EPS Growth
- RDHL N/A
- MBIO N/A
- EPS
- RDHL N/A
- MBIO N/A
- Revenue
- RDHL $3,707,000.00
- MBIO N/A
- Revenue This Year
- RDHL $224.90
- MBIO N/A
- Revenue Next Year
- RDHL $82.69
- MBIO N/A
- P/E Ratio
- RDHL N/A
- MBIO N/A
- Revenue Growth
- RDHL N/A
- MBIO N/A
- 52 Week Low
- RDHL $2.40
- MBIO $1.20
- 52 Week High
- RDHL $20.28
- MBIO $65.00
- Technical
- Relative Strength Index (RSI)
- RDHL 26.68
- MBIO 33.40
- Support Level
- RDHL $2.64
- MBIO $1.20
- Resistance Level
- RDHL $2.90
- MBIO $1.51
- Average True Range (ATR)
- RDHL 0.23
- MBIO 0.11
- MACD
- RDHL 0.07
- MBIO 0.11
- Stochastic Oscillator
- RDHL 6.76
- MBIO 77.42
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.